June 22, 2020 / 1:19 PM / 18 days ago

BRIEF-Arcutis Enrolls Last Patient In Phase 2 Proof Of Concept Clinical Trial Evaluating Arq-154

June 22 (Reuters) - Arcutis Biotherapeutics Inc:

* ARCUTIS ENROLLS LAST PATIENT IN PHASE 2 PROOF OF CONCEPT CLINICAL TRIAL EVALUATING ARQ-154 (TOPICAL ROFLUMILAST FOAM) AS A POTENTIAL TREATMENT FOR SEBORRHEIC DERMATITIS

* ARCUTIS BIOTHERAPEUTICS INC - PHASE 2 TOPLINE DATA ANTICIPATED EARLY IN Q4 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below